WO2000023471A3 - Use of a cytokine-producing lactococcus strain to treat colitis - Google Patents

Use of a cytokine-producing lactococcus strain to treat colitis Download PDF

Info

Publication number
WO2000023471A3
WO2000023471A3 PCT/EP1999/007800 EP9907800W WO0023471A3 WO 2000023471 A3 WO2000023471 A3 WO 2000023471A3 EP 9907800 W EP9907800 W EP 9907800W WO 0023471 A3 WO0023471 A3 WO 0023471A3
Authority
WO
WIPO (PCT)
Prior art keywords
cytokine
lactococcus strain
treat colitis
producing lactococcus
producing
Prior art date
Application number
PCT/EP1999/007800
Other languages
French (fr)
Other versions
WO2000023471A2 (en
Inventor
Lothar Steidler
Erik Rene Remaut
Walter Fiers
Original Assignee
Vlaams Interuniv Inst Biotech
Lothar Steidler
Erik Rene Remaut
Walter Fiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Interuniv Inst Biotech, Lothar Steidler, Erik Rene Remaut, Walter Fiers filed Critical Vlaams Interuniv Inst Biotech
Priority to AT99950738T priority Critical patent/ATE259829T1/en
Priority to EP99950738A priority patent/EP1123314B1/en
Priority to JP2000577196A priority patent/JP4598954B2/en
Priority to AU63401/99A priority patent/AU770726B2/en
Priority to CA2343840A priority patent/CA2343840C/en
Priority to DE69914932T priority patent/DE69914932T2/en
Publication of WO2000023471A2 publication Critical patent/WO2000023471A2/en
Publication of WO2000023471A3 publication Critical patent/WO2000023471A3/en
Priority to US09/838,718 priority patent/US6746671B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The current invention relates to an administraton strategy for the delivery at the intestinal mucosa of cytokines or cytokine antagonists, preferably of acid sensitive anti-inflammatory agents, such as IL10 and/or soluble TNF receptor via the oral route. The prefered feature according to the invention is the inoculation with a suspension of recombinant Lactococcus lactis cells, which had been engineered to produce the respective proteins.
PCT/EP1999/007800 1998-10-20 1999-10-06 Use of a cytokine-producing lactococcus strain to treat colitis WO2000023471A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AT99950738T ATE259829T1 (en) 1998-10-20 1999-10-06 USE OF A CYTOKINE-PRODUCING LACTOCOCCUS STRAIN FOR THE TREATMENT OF COLITIS
EP99950738A EP1123314B1 (en) 1998-10-20 1999-10-06 Use of a cytokine-producing lactococcus strain to treat colitis
JP2000577196A JP4598954B2 (en) 1998-10-20 1999-10-06 Use of cytokine-producing Lactococcus strains for the treatment of colitis
AU63401/99A AU770726B2 (en) 1998-10-20 1999-10-06 Use of a cytokine-producing lactococcus strain to treat colitis
CA2343840A CA2343840C (en) 1998-10-20 1999-10-06 Use of a cytokine-producing lactococcus strain to treat colitis
DE69914932T DE69914932T2 (en) 1998-10-20 1999-10-06 USE OF A CYTOKINE-PRODUCING LACTOCOCCUS TRIBE FOR TREATING COLUMN
US09/838,718 US6746671B2 (en) 1998-10-20 2001-04-19 Use of a cytokine-producing lactococcus strain to treat colitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203529.7 1998-10-20
EP98203529 1998-10-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/838,718 Continuation US6746671B2 (en) 1998-10-20 2001-04-19 Use of a cytokine-producing lactococcus strain to treat colitis

Publications (2)

Publication Number Publication Date
WO2000023471A2 WO2000023471A2 (en) 2000-04-27
WO2000023471A3 true WO2000023471A3 (en) 2000-08-03

Family

ID=8234239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/007800 WO2000023471A2 (en) 1998-10-20 1999-10-06 Use of a cytokine-producing lactococcus strain to treat colitis

Country Status (9)

Country Link
US (1) US6746671B2 (en)
EP (1) EP1123314B1 (en)
JP (2) JP4598954B2 (en)
AT (1) ATE259829T1 (en)
AU (1) AU770726B2 (en)
CA (1) CA2343840C (en)
DE (1) DE69914932T2 (en)
ES (1) ES2214049T3 (en)
WO (1) WO2000023471A2 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
DE69914932T2 (en) 1998-10-20 2004-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. USE OF A CYTOKINE-PRODUCING LACTOCOCCUS TRIBE FOR TREATING COLUMN
FR2785809B1 (en) * 1998-11-18 2001-01-12 Gervais Danone Sa SELECTION AND USES OF STRAINS OF LACTIC BACTERIA MODULATING NON-SPECIFIC IMMUNITY
ID29150A (en) * 1999-01-15 2001-08-02 Entpr Ireland Cs USE OF LACTOBACILLUS SALIVARIUS
DK1739178T3 (en) * 1999-07-05 2010-11-22 Actogenix Nv Delivery of threefold peptides
JP4624574B2 (en) * 2000-05-31 2011-02-02 株式会社ヤクルト本社 Lipid peroxidation inhibitor
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
JP5116194B2 (en) * 2001-09-04 2013-01-09 株式会社ヤクルト本社 Inflammatory bowel disease preventive and therapeutic agent
US7442546B2 (en) * 2002-03-15 2008-10-28 The Regents Of The University Of Michigan Method of modulating inflammatory response
AU2003214038A1 (en) * 2002-04-03 2003-10-13 Chr. Hansen A/S Peptides with anti-hypertensive properties
EP1513545B1 (en) * 2002-06-19 2008-03-19 Actogenix N.V. Methods and means to promote gut absorption
JP2006520584A (en) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． Stabilized single domain antibody
AU2003286004A1 (en) 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
CA2506031A1 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
US7718171B2 (en) * 2003-04-07 2010-05-18 Chr. Hansen A/S Reducing heart rate in mammals using milk derived fermentation products produced using Lactobacillus helveticus
US20060177424A1 (en) * 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US8192733B2 (en) * 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
MX2007012755A (en) 2005-04-15 2008-01-14 Univ North Carolina State Methods and compositions to modulate adhesion and stress tolerance in bacteria.
US9017662B2 (en) 2005-08-30 2015-04-28 Actogenix N.V. Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
EP1934349A4 (en) * 2005-08-30 2009-05-27 Commw Scient Ind Res Org Bacterial delivery of biologically active polypeptides
US8246946B2 (en) * 2005-09-27 2012-08-21 Cobb & Associates Treatment of bipolar disorder utilizing anti-fungal compositions
EP1931762B1 (en) * 2005-10-03 2012-12-05 Actogenix N.V. Use of recombinant yeast strain producing an anti -inflammatory compound in the manufacture of a medicament to treat colitis
EP1957100B1 (en) 2005-11-29 2016-07-13 Intrexon Actobiotics NV Induction of mucosal tolerance to antigens
US8846102B2 (en) * 2006-03-30 2014-09-30 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
WO2007133188A1 (en) * 2006-05-01 2007-11-22 Cobb & Company, Llp Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
BRPI0711119A2 (en) * 2006-05-02 2011-08-30 Actogenix Nv microbial administration of obesity-associated intestinal peptides
CA2655990A1 (en) * 2006-06-22 2007-12-27 Tai June Yoo Restoration of hearing loss
US20100303777A1 (en) * 2006-12-14 2010-12-02 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
AU2008204442B2 (en) 2007-01-12 2013-03-14 Intrexon Actobiotics Nv Lactococcus promoters and uses thereof
EP2125010B1 (en) 2007-01-25 2014-06-04 Actogenix N.V. Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus
EP1972350A1 (en) * 2007-03-20 2008-09-24 Rijksuniversiteit Groningen Dual targeting system
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
JP2012504116A (en) * 2008-09-29 2012-02-16 アクトジェニックス・エヌブイ Reduction of microbial colonization in the mucosa
DK2424972T3 (en) 2009-04-30 2013-10-14 Actogenix Nv Cryoprotectants for freeze-drying of lactic acid bacteria
EP3192873A1 (en) 2009-09-29 2017-07-19 Intrexon Actobiotics NV Lactobacillus and streptococcus promoters and uses thereof
WO2011059332A2 (en) * 2009-11-16 2011-05-19 Stichting Top Institute Food And Nutrition Improved immunomodulation by probiotics
IN2012DN05169A (en) * 2009-12-02 2015-10-23 Acceleron Pharma Inc
EP2343319A1 (en) 2010-01-07 2011-07-13 University of Ljubljana Genetically modified food grade microorganism for treatment of inflammatory bowel disease
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
AU2011268146A1 (en) 2010-06-17 2013-01-10 Actogenix Nv Compositions and methods for treating inflammatory conditions
JP5991650B2 (en) * 2010-08-10 2016-09-14 国立研究開発法人農業・食品産業技術総合研究機構 Porcine erysipelas expressing cytokines and delivery method of cytokines using swine erysipelas
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
JP6175428B2 (en) 2011-06-01 2017-08-02 イントレクソン・アクトバイオテイクス・エヌブイＩｎｔｒｅｘｏｎ Ａｃｔｏｂｉｏｔｉｃｓ ＮＶ Bacterial polycistronic expression system
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc Compositions and methods for increasing serum half-life
HUE038336T2 (en) 2011-09-23 2018-10-29 Intrexon Actobiotics Nv Modified gram positive bacteria and uses thereof
ES2676707T3 (en) 2011-09-23 2018-07-24 Intrexon Actobiotics Nv Modified gram positive bacteria and their uses
BR112014024159A2 (en) 2012-03-29 2017-06-20 Therabiome Llc GASTROINTESTINAL SITE-SPECIFIC ORAL VACCINE FORMULATIONS ACTIVE IN THE ILUM AND APPENDIX.
KR101599769B1 (en) * 2012-08-10 2016-03-04 한국생명공학연구원 A novel Lactococcus sp. strain and use thereof
CN102854165A (en) * 2012-09-03 2013-01-02 重庆市畜牧科学院 Method for rapidly determining number of bacterial in lactic acid bacillus subtilis production liquid culture
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
FR3007655B1 (en) * 2013-06-28 2016-12-23 Lesaffre & Cie BACILLUS SUBTILIS STRAIN FOR THE TREATMENT AND / OR PREVENTION OF CHRONIC INFLAMMATORY DISEASES
US10383921B2 (en) * 2013-08-13 2019-08-20 President And Fellows Of Harvard College Leveraging oxidative stress pathways in lactic acid bacteria to promote gut homeostasis
DK3402499T3 (en) 2016-01-14 2021-09-27 Intrexon Actobiotics Nv COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF TYPE 1 DIABETES
WO2017184565A1 (en) 2016-04-20 2017-10-26 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for nucleic acid expression and protein secretion in bacteroides
KR101898138B1 (en) * 2016-05-12 2018-09-12 주식회사 이뮤너스 Aquaculture functional feed additive comprising Lactococcus lactis BFE920 inducing regulatory T Cell
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN117986337B (en) * 2024-02-02 2024-08-16 杭州御寿生物科技有限公司 Probiotic composition for improving immunity and application thereof in treatment of diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011277A1 (en) * 1994-10-05 1996-04-18 Dompe' S.P.A. Microorganisms as therapeutic delivery systems
WO1997014806A2 (en) * 1995-10-20 1997-04-24 Cambridge University Technical Services Limited Delivery of biologically active polypeptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2145744T5 (en) * 1991-01-18 2008-02-01 Amgen Inc. PROCEDURES FOR TREATING DISEASES INDUCED BY THE TUMOR NECROSIS FACTOR.
CZ283488B6 (en) * 1992-08-20 1998-04-15 Schering Corporation Use of il-10 for preparing a medicament and treating inflammatory internal disease
WO1995015179A1 (en) * 1993-12-01 1995-06-08 Unisearch Limited Method of treating intestinal disorders
JP2000508645A (en) * 1996-04-12 2000-07-11 ペプテック リミテッド Method for treating immune diseases using polyunsaturated fatty acids
DE69914932T2 (en) * 1998-10-20 2004-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. USE OF A CYTOKINE-PRODUCING LACTOCOCCUS TRIBE FOR TREATING COLUMN

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011277A1 (en) * 1994-10-05 1996-04-18 Dompe' S.P.A. Microorganisms as therapeutic delivery systems
WO1997014806A2 (en) * 1995-10-20 1997-04-24 Cambridge University Technical Services Limited Delivery of biologically active polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEIDLER L ET AL: "Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine.", INFECTION AND IMMUNITY, (1998 JUL) 66 (7) 3183-9. JOURNAL CODE: GO7. ISSN: 0019-9567., United States, XP002105819 *

Also Published As

Publication number Publication date
JP2002528392A (en) 2002-09-03
DE69914932T2 (en) 2004-12-09
ATE259829T1 (en) 2004-03-15
CA2343840A1 (en) 2000-04-27
US6746671B2 (en) 2004-06-08
JP2010222364A (en) 2010-10-07
WO2000023471A2 (en) 2000-04-27
US20020019043A1 (en) 2002-02-14
AU6340199A (en) 2000-05-08
ES2214049T3 (en) 2004-09-01
AU770726B2 (en) 2004-02-26
JP4598954B2 (en) 2010-12-15
EP1123314B1 (en) 2004-02-18
CA2343840C (en) 2011-03-08
DE69914932D1 (en) 2004-03-25
EP1123314A2 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
WO2000023471A3 (en) Use of a cytokine-producing lactococcus strain to treat colitis
ES2272311T3 (en) SUPPLY OF PEPTIDES TREBOL.
JP2002519061A5 (en)
EP1095695A3 (en) Novel polyimide amic acid salts and polyimide membranes formed therefrom
AU7587696A (en) Differentiation-suppressive polypeptide
WO2000003683A3 (en) Liposomal encapsulated nucleic acid-complexes
AUPR107800A0 (en) Peptide and nucleic acid molecule ii
JPH10506791A (en) Microorganisms as therapeutic delivery systems
PT1165791E (en) Human cytokine as ligand of the zalpha receptor and uses thereof
US20080254014A1 (en) Use of Recombinant Yeast Strain Producing an Anti-Inflammatory Compound to Treat Colitis
WO2004035618A3 (en) Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
BG103016A (en) Polypeptides capable of forming antigen-binding structures of specificity to rhesus d antigens, their encoding dna and method for their prparation and application
WO2003087757A3 (en) Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods
IL141869A0 (en) Mammalian transforming growth factor beta-9 (ztgfss9)
WO1999054353A3 (en) Human nucleic acid sequences of normal uterus tissue
WO2002077249A3 (en) Type iii bacterial strains for use in medicine
JP2004520009A5 (en)
WO2001049831A3 (en) Xylosyltransferase and isoforms thereof
WO2002068662A8 (en) Plasmid originated from bifidobacterium, recombinant expression vector using the plasmid and transformation method
WO2001094414A3 (en) THE HUMAN VOLTAGE GATED SODIUM CHANNEL β-1A SUBUNIT AND METHODS OF USE
WO2000010506A3 (en) Angiogenesis inhibitors and uses thereof
WO2002060382A3 (en) Novel compounds and uses thereof
WO2000006735A8 (en) Interferon alpha hybrids
IL158223A0 (en) Peptidylarginine deiminase 6
WO2001040257A3 (en) Modified il-12 subunits and nucleic acids encoding them

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 63401

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2343840

Country of ref document: CA

Ref country code: CA

Ref document number: 2343840

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 63401/99

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 577196

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999950738

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09838718

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999950738

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1999950738

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 63401/99

Country of ref document: AU